Management Report
Performance by Subgroup and Segment
Group structure
Bayer AG, headquartered in Leverkusen, Germany, is the strategic management holding company for the Bayer Group. Business activities are conducted by the HealthCare, CropScience and MaterialScience subgroups, supported by the service companies Bayer Business Services, Bayer Technology Services and CURRENTA. There have been no material changes to the Bayer Group’s structure since the 2006 Annual Report.
The commentaries in this report relate exclusively to continuing operations, except where specific reference is made to discontinued operations or to a total value (total). The divested activities of the Diagnostics Division from the HealthCare subgroup and of H.C. Starck and Wolff Walsrode from the MaterialScience subgroup are reported as discontinued operations. The prior-year figures have been restated accordingly.
The acquired business of Schering, Berlin, Germany, is included in the Pharmaceuticals segment of the HealthCare subgroup as of June 23, 2006. As of December 31, 2007, our interest in the voting capital of Bayer Schering Pharma AG, Berlin, Germany, amounted to 96.3 percent. The names “Bayer Schering Pharma” or “Schering” as used in this report always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively. The reference to Bayer Schering Pharma AG or Schering AG also includes business conducted by affiliated entities in countries outside Germany. Bayer Schering Pharma AG and Schering-Plough Corporation, New Jersey, U.S., are unaffiliated companies that have been totally independent of each other for many years.
The commentaries in this report relate exclusively to continuing operations, except where specific reference is made to discontinued operations or to a total value (total). The divested activities of the Diagnostics Division from the HealthCare subgroup and of H.C. Starck and Wolff Walsrode from the MaterialScience subgroup are reported as discontinued operations. The prior-year figures have been restated accordingly.
The acquired business of Schering, Berlin, Germany, is included in the Pharmaceuticals segment of the HealthCare subgroup as of June 23, 2006. As of December 31, 2007, our interest in the voting capital of Bayer Schering Pharma AG, Berlin, Germany, amounted to 96.3 percent. The names “Bayer Schering Pharma” or “Schering” as used in this report always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively. The reference to Bayer Schering Pharma AG or Schering AG also includes business conducted by affiliated entities in countries outside Germany. Bayer Schering Pharma AG and Schering-Plough Corporation, New Jersey, U.S., are unaffiliated companies that have been totally independent of each other for many years.
Key Data by Subgroup and Segment, 2007
| Sales | EBIT before special items* | EBITDA before special items* | EBITDA margin before special items* | |||||
| € million | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 | 2006 | 2007 |
| HealthCare | 11,724 | 14,807 | 1,715 | 2,492 | 2,613 | 3,792 | 22.3% | 25.6% |
| Pharmaceuticals | 7,478 | 10,267 | 934 | 1,641 | 1,686 | 2,807 | 22.5% | 27.3% |
| Consumer Health | 4,246 | 4,540 | 781 | 851 | 927 | 985 | 21.8% | 21.7% |
| CropScience | 5,700 | 5,826 | 641 | 786 | 1,204 | 1,324 | 21.1% | 22.7% |
| Crop Protection | 4,644 | 4,781 | 441 | 632 | 927 | 1,093 | 20.0% | 22.9% |
| Environmental Science/BioScience | 1,056 | 1,045 | 200 | 154 | 277 | 231 | 26.2% | 22.1% |
| MaterialScience | 10,161 | 10,435 | 1,210 | 1,117 | 1,677 | 1,606 | 16.5% | 15.4% |
| Materials | 2,925 | 3,041 | 289 | 100 | 448 | 273 | 15.3% | 9.0% |
| Systems | 7,236 | 7,394 | 921 | 1,017 | 1,229 | 1,333 | 17.0% | 18.0% |
| Reconciliation | 1,371 | 1,317 | (87) | (108) | 90 | 55 | 6.6% | 4.2% |
| Continuing operations | 28,956 | 32,385 | 3,479 | 4,287 | 5,584 | 6,777 | 19.3% | 20.9% |
* for definition see Bayer Group Key Data, also Calculation of EBIT(DA) Before Special Items



Chairman’s Letter
Performance by Subgroup and Segment
Bayer Links
Investor Relations

Bookmark this page
E-mail this page
Advanced Search

